PHILADELPHIA, June 2, 2016 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters has announced the launch of Precision Medicine Intelligence, a new evidence-based solution dedicated to helping scientists and physicians understand and keep pace with the rapid growth of scientific and medical literature.
The announcement was made today at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, an annual gathering of over 30,000 oncology professionals from around the world, held at McCormick Place in Chicago, Illinois.
The Thomson Reuters Precision Medicine Intelligence provides a structured database of evidence-based clinical outcomes designed to empower concise, accurate and clinically meaningful interpretation of molecular test results. This helps users to keep up to date with genomics knowledge to validate and interpret relevant variant associations, translating the complexity of gene data into clinically actionable insights. Precision Medicine Intelligence also supports patient segment definition and stratification for clinical research, accelerating drug development to ultimately drive new research and clinical development strategies.
The solution, which is delivered via an API and through partner platforms, integrates intelligence from a wide variety of global sources, including full text peer-reviewed journals, clinical guidelines, clinical trials and regulatory drug approvals. Drawing on Thomson Reuters' decades of expertise in curating trusted scientific content for professionals, Precision Medicine Intelligence provides manually selected content in the following areas:
-Variants: Genomic variants and their association to disease and drug response, coupled with rich indexing, empower a computational pipeline that identifies the key variants based on known phenotypic affect
-Clinical Trials: Recruiting clinical trials along with their inclusion/exclusion criteria, allows identification of trials in your area suitable for your patients
-Drugs: A comprehensive collection of both investigational and launched drugs with approval status by indication and by country, coupled with biological indexing of the drug's mechanism of action
-Gene Biomarkers: Additional content on known biomarkers and their role, supplements the curated variant association records
"With the launch of the Precision Medicine Intelligence, we're empowering researchers to speed up the development of safer and more effective drugs, and providing oncologists with invaluable insights to scale up the process for genomics reporting in the clinic," said Richard Neale, Global Head of Life
Sciences at Thomson Reuters. "The Life Sciences business is proud to contribute to these efforts, and excited to provide high value curated content to this important initiative which continues to accelerate both research while improving health at the individual patient level."
Learn more about the Precision Medicine Intelligence, visit booth #8129 at the 2016 ASCO Annual Meeting, or visit http://tmsnrt.rs/1Xujawj
Thomson Reuters is the world's leading source of news and information for professional markets. Our customers rely on us to deliver the intelligence, technology and expertise they need to find trusted answers. The business has operated in more than 100 countries for more than 100 years. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges (symbol: TRI). For more information, visit www.thomsonreuters.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thomson-reuters-launches-new-precision-medicine-intelligence-300278767.html
SOURCE Intellectual Property and Science business of Thomson Reuters